Next Phase Newsletter

A single family office based in New York, NY. The group has significant experience in the healthcare space and has made several successful investments in a variety of life science companies. Initial investments can range widely depending on the needs and stage of development of the company, with allocations from $100K – $4M. Investments may come in the form of straight equity or convertible notes. The firm may lead or co-invest in a syndicate and typically looks to take a meaningful stake in portfolio companies. The group may seek a board seat depending on the size of the investment and their role in the financing round, however it is not a requirement.

The firm is fairly opportunistic in the healthcare space and is interested in therapeutics, medical devices and increasingly digital health/healthcare IT, however the group favors breakthrough technologies. As for therapeutics, The firm is most interested in companies with POC/Ph. II data, but will evaluate companies with some earlier clinical data as well. In the medical device space, the group will consider companies yet to obtain FDA approval, but looks for companies with a clear path to approval and commercialization. The firm has historically focused on biotech and medtech companies, but plans to become more active in the healthcare IT space going forward.

The firm has no strict management team requirements, but favors strong management teams with considerable experience. The group tends to focus on U.S.-based companies, but has no geographic restrictions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The venture capital arm of a major health system looks to invest between $500K – $5M, in Seed, Series A and Series B rounds. The firm is looking to invest in technologies that can be leveraged by a large healthcare system. The group is currently looking for opportunities throughout the United States.

The firm is looking to invest in companies with strong ROI potential that also are strategically aligned with the group’s parent healthcare system. The group is interested in companies meeting this criteria operation in the digital health, medical devices and diagnostics. The group is open to investing in companies that are pre-revenue, including those with a product still in development or in clinical trials. The firm does not invest in therapeutics or Class III medical devices.

The firm is looking for companies with experienced management teams and generally seeks board representation following investment. The group is also interested in forming joint-ventures or co-development programs when relevant and looks to leverage its connection to the firm to aid companies as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large pharmaceutical company based in China that is one of the top private enterprises in the country, is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm currently manages two funds with over $200 million AUM and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare and life sciences investments.

On average, the size of investment is $10M, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can invest both public and private companies in a broad variety of types and transaction structures including growth capital, buyouts, late-stage developments (with proof of concept), and recapitalizations. The firm looks for companies located around the globe, with a preference in the US, Europe, and Japan. The firm is willing to both lead and co-invest in companies located around the globe, while co-invest is their sweet spot.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm is open to all kinds of sectors and indications with preferences in antivirus, oncology, neurosciences, and diabetes. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase I, and from phase III to on-the-market; while middle stage products might be a less focus. Regarding medical devices and diagnostics, the firm will invest at any stage of development. The firm is willing to consider companies targeting orphan indications.

The firm can invest in both private and public companies. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture capital firm located in the USA East Coast focuses on life science companies that develop enabling tools, technologies and services for discovery, development and manufacturing of biologics and related therapies. The firm is focused on early stage venture and growth equity investments. Typical equity investments range from $500k-$5 million. The firm expects to make 6-10 investments in the coming 18 months and is open to either leading or following in a financing round. The firm is currently seeking opportunities from the US, Canada, and Europe.

Within life sciences, the firm is specifically focused on tools, technologies and services that enable the discovery, development and production of life-saving therapies and deliver on the biopharmaceutical industry’s evolution towards lower costs, and increased access to medicines globally. Examples may include immunotherapy, bioinformatics, RNA therapy, synthetic biology. The firm considers Seed- to Series A/B- stage opportunities.

The firm partners with entrepreneurs and their teams to overcome inflection points in growth. The firm takes a hands-on approach to working with its portfolio companies through focused operational and commercial guidance and an engaged approach to supporting entrepreneurial ventures.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture firm based in New York is currently raising its first investment fund, with a target of $40 million. The firm focuses on early stage healthcare startups, and may consider leading investment rounds in addition to making co-investments. The firm will consider investment opportunities worldwide, with a focus on North America.

The firm focuses on digital health, and will also consider medical device and diagnostic opportunities. The firm looks broadly at new technologies in these sectors and has high interest in technologies for senior living, wellness, and driving down the costs of healthcare. The firm prefers to invest in platform opportunities rather than companies with a single product or app.

The firm is interested in being a good partner for their portfolio companies, leveraging the firm’s expertise in healthcare and connections to major health providers and public corporations in the healthcare sector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm that was founded in 2016 with offices throughout USA and Asia, consists of limited partners including institutional investors from US and China. Currently the firm is investing from its $180 million fund into the healthcare sector. Typical equity investments range from US $5-10 million in businesses from Series A to pre-IPO and public traded companies. The firm is open to leading or following a syndicated round. The firm is now seeking opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observership on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the USA has several decades of experience in investing in life science companies and taking them public. The firm participates in deals across all stages of development, from seed to mezzanine funding. In early-stage deals, the firm’s initial check size is usually between $250-500K, with potential for follow-on financing as the companies achieve key growth milestones. The firm is actively involved with a well-established angel investor group and makes investments through this group as well. The firm is open to opportunities all across the globe.

The firm seeks to invest broadly across different silos of the life sciences ecosystem, from therapeutics, devices, diagnostics, and digital health. The firm’s strongest interest and expertise lies in biotech, and many of the firm’s investments have been in therapeutics companies. The firm is also open to companies of all stages of development and is indication agnostic, but has significantly higher standards for oversaturated, competitive spaces such as oncology.

The firm has no explicitly stated company or management team requirements. The firm likes to become actively involved in their portfolio companies and supports them with needed resources and advisory services to help them grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.